Century Therapeutics Significantly Expands Capabilities with New Operational, Laboratory and Manufacturing Facilities in Pennsylvania and New Jersey

← Back to News & Events

Share: Twitter Facebook

PHILADELPHIA, Feb. 17, 2021 /PRNewswire/ — Century Therapeutics, a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, today announced a significant expansion of its operational and laboratory space in Philadelphia, as well as progress on its manufacturing facility in Branchburg, NJ, paving the way for a strong technical foundation as the company scales up its in-house research and development capabilities.

The company is expanding its presence in uCity Square, opening 17,000 square feet of mixed office and laboratory space at 3624 Market Street, an additional 5,000 square feet of space at 3711 Market Street and has signed a lease for 25,000 square feet at 3535 Market Street – all within steps of the current headquarters at 3675 Market Street. Century has also committed to 33,000 square feet in the One uCity life sciences development currently under construction in the same burgeoning region of the city. “We are excited to expand our footprint within the heart of Philadelphia – which has emerged as an epicenter of the growing cell and gene therapy field,” said Lalo Flores, PhD, Chief Executive Officer of Century Therapeutics. “This new space will not only boost community vitality and fuel the local economy, but it will also enable us to accelerate development of our genetically engineered, universal iPSC-derived immune effector cell products – including iNK and iT cells – and ultimately reach more cancer patients.”

Read more at APNews.com